文献速递头颈部肿瘤放疗

吐舌放疗通过降低口腔舌剂量促进头颈癌放疗后味觉障碍快速恢复

Tongue-Out Radiation Therapy for Patients With Head and Neck Cancer Facilitated a Rapid Recovery From Post-Radiation Therapy Dysgeusia by Lowering Oral Tongue Dose.
PubMed 文献 · Pract Radiat Oncol · 2026-01-02

该回顾性研究纳入14例接受吐舌放疗(TORT)的头颈癌患者,将口腔舌前移出嘴外并单独勾画为OTOUT,评估味觉变化。结果显示OTOUT平均剂量为13.3±2.9 Gy,低于口腔舌的26.4±6.8 Gy;TORT结束时重度味觉障碍比例从基线14%升至86%(P<.01),但1个月后降至43%(P<.01),3个月和6个月时患者报告味觉质量恢复至基线水平。

要点

  • TORT将口腔舌前移出嘴外,OTOUT平均剂量为13.3±2.9 Gy,低于口腔舌的26.4±6.8 Gy。
  • TORT结束时重度味觉障碍比例从基线14%升至86%(P<.01),1个月后降至43%(P<.01)。
  • 3个月和6个月时患者报告味觉质量恢复至基线水平(P=.23和P=.18)。

核心结论

  • TORT通过前移口腔舌降低口腔舌尤其是OTOUT的平均剂量,促进头颈癌患者放疗后1个月味觉快速恢复。
  • 患者报告味觉质量在TORT后3个月和6个月恢复至基线水平。
  • 需要进一步随机研究验证TORT对头颈癌的临床优势。

研究设计与样本

  • 回顾性研究,纳入14例接受TORT的头颈癌患者,根治或挽救剂量70 Gy,辅助剂量60-66 Gy,可同步化疗。
  • 采用华盛顿大学生存质量问卷第4版第9题评估患者报告味觉质量,于TORT前、结束时及后1、3、6个月进行。
  • 按指南勾画口腔(OC)和口腔舌(OT),前移出嘴外的OT部分单独勾画为OTOUT,统计分析采用χ2检验和t检验,P<.05为显著。

主要发现

  • 14例TORT计划中,OC和OT平均体积分别为105.8±25.3和67.6±20.7 cm³,OTOUT占整个OT体积的20%(13.4±9.1 cm³)。
  • OC、OT和OTOUT的平均平均剂量(DMEAN)分别为25.2±6.9、26.4±6.8和13.3±2.9 Gy。
  • TORT前无至轻度味觉障碍与≥重度味觉障碍的患者比例分别为86%(n=12)和14%(n=2);TORT结束时分别为14%(n=2)和86%(n=12),P<.01。
  • TORT后1个月无至轻度与≥重度味觉障碍比例分别为57%(n=8)和43%(n=6),P<.01;3个月分别为79%(n=11)和21%(n=3),P=.23;6个月分别为93%(n=13)和7%(n=1),P=.18。

临床怎么用

  • 对接受头颈癌放疗的患者,可考虑采用TORT技术将口腔舌前移出照射野以降低舌剂量。
  • TORT可能有助于加速放疗后味觉障碍的恢复,尤其在治疗后1个月。
  • 需关注患者报告味觉质量,在3个月和6个月时评估恢复情况。

局限性

  • 回顾性研究,样本量小(14例),缺乏对照组。
  • 需要进一步随机研究验证临床优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the rapid recovery of treatment-related dysgeusia after tongue-out radiation therapy (TORT) for head and neck cancer (HNC). METHODS AND MATERIALS: We retrospectively reviewed 14 patients with HNC who completed TORT with 70 Gy for definitive or salvage and 60 to 66 Gy for adjuvant treatment with or without concurrent chemotherapy. Patient-reported quality of taste was evaluated before, at the end of TORT therapy, and periodically 1, 3, and 6 months after TORT therapy using the University of Washington Quality of Life questionnaire version 4, question 9, including options for no-, mild-, and severe dysgeusia and ageusia. Oral cavity (OC) and oral tongue (OT) were contoured following guidelines. A portion of the anteriorly displaced OT outside the mouth was separately contoured as OTOUT. Statistical analysis was conducted with the χ2 and t test. A probability level of P < .05 was considered significant. RESULTS: In 14 TORT plans, the average volume of OC and OT was 105.8 ± 25.3 and 67.6 ± 20.7 cm3, respectively. OTOUT comprised 20% (13.4 ± 9.1 cm3) of the entire OT volume. Average mean dose (DMEAN) to OC, OT, and OTOUT was 25.2 ± 6.9, 26.4 ± 6.8, and 13.3 ± 2.9 Gy, respectively. Before TORT, no-to-mild versus equal or higher than severe dysgeusia (≥ severe dysgeusia) was 86% (n = 12) versus 14% (n = 2) of patients, respectively; 14% (n = 2) versus 86% (n =12) at the end of TORT (P < .01); 57% (n = 8) versus 43% (n = 6) at 1-month post-TORT (P < .01); 79% (n = 11) versus 21% (n = 3) at 3-month post-TORT (P = .23) and 93% (n = 13) versus 7% (n = 1) at 6-month post-TORT (P = .18). CONCLUSION: TORT displaced OT anteriorly, lowered DMEAN to OT, especially to OTOUT, and facilitated rapid regaining of sense of taste at 1-month post-TORT. Patient-reported quality of taste returned to the baseline at 3-month and 6-month post-TORT. Further randomized study to verify clinical advantages with TORT for HNC is warranted.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kil WJ, Stiffler A, Smith W, et al. Tongue-Out Radiation Therapy for Patients With Head and Neck Cancer Facilitated a Rapid Recovery From Post-Radiation Therapy Dysgeusia by Lowering Oral Tongue Dose. Pract Radiat Oncol. 2026. PMID: 41485539. doi:10.1016/j.prro.2025.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。